Sign In
Buy HUGE
$0.0899
+0 (+0%)
At Close: Nov 15, 2024
Court of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million
07:00am, Tuesday, 06'th Feb 2024
TORONTO, ON / ACCESSWIRE / February 6, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innova
FSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate Updates
04:30pm, Monday, 29'th Jan 2024
TORONTO, ON / ACCESSWIRE / January 29, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innova
Update Provided on GBB Drink Lab, Inc. Litigation and Safety Shot
07:30am, Tuesday, 16'th Jan 2024
TORONTO, ON / ACCESSWIRE / January 16, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), is a biopharmaceutical company dedicated to building a portfolio of inn
GBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case
01:11pm, Thursday, 11'th Jan 2024
The Court concludes that Plaintiff has sufficiently demonstrated that its trade secrets derived economic value from not being readily ascertainable by others Clearwater, FL.
TORONTO, ON / ACCESSWIRE / December 22, 2023 / FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of inn
FSD Pharma Inc. Announces Closing of Private Placement
09:00am, Tuesday, 05'th Dec 2023
TORONTO, ON / ACCESSWIRE / December 5, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) (the "Company" or "FSD"), is pleased to announce that, further to its news release on November 27, 2023,
Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market TORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Comp
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
08:50am, Monday, 08'th May 2023
TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portf
FSD Pharma receives regulatory clearance for proposed Phase 1 clinical trial of multiple sclerosis drug candidate Lucid-MS
10:14am, Tuesday, 07'th Feb 2023
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) told investors it has received a No Objection Letter (NOL) from Health Canada for its proposed Phase 1 clinical trial of LUCID-21-302 (Lucid-MS), a novel drug ca
FSD Pharma says recruiting underway in Phase 2 Trial of FSD201 for treating chronic pain associated with idiopathic MCAS
09:09am, Monday, 30'th Jan 2023
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said recruiting is underway for the Phase 2 clinical trial of FSD-PEA (FSD201) for the treatment of chronic pain associated with idiopathic Mast Cell Activatio
FSD Pharma submits clinical trial application for its multiple sclerosis treatment candidate Lucid-MS
10:12am, Tuesday, 17'th Jan 2023
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) announced it has submitted a Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS, a candidate for the treatment of multiple sclero
FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reserves
09:46am, Friday, 13'th Jan 2023
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up to 1.9 million of its subordinate Class B voting s
FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in Australia
10:18am, Monday, 09'th Jan 2023
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The Toronto-based biopharma firm told investors i
FSD Pharma announces changes to its board of directors
07:18am, Tuesday, 29'th Nov 2022
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the appointments of Dr Lakshmi P. Kotra and Joseph L.
FSD Pharma wins FDA and Health Canada approval for IND for Phase 2 Trial of FSD201 for treating inflammatory disorder
10:48am, Tuesday, 06'th Sep 2022
FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) revealed that it has received a study may proceed letter for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and n
